Home › All Companies › ABPWW › Annual Report

Abpro Holdings, Inc. (ABPWW) — Annual Report

AI-Powered SEC Filing Analysis

← All ABPWW filings
Latest Annual Report Filed: 2026-04-15

Key Insights

  • Abpro Holdings is a development-stage biotech company with no commercialized products, raising substantial doubt about its ability to continue as a going concern.
  • The company has in-licensed intellectual property related to its lead product candidate ABP-201 from AstraZeneca, but is currently in breach of the license agreement terms.
  • Abpro's common stock and warrants have been delisted from Nasdaq and are now trading on the OTC Pink Ltd. tier, indicating significant financial and operational challenges.
Sentiment: Negative Significance: 8/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Abpro Holdings, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.